Randomised clinical trial: once‐ vs. twice‐daily prolonged‐release mesalazine for active ulcerative colitis

Abstract

When combined with mesalazine enema, prolonged-release mesalazine once-daily 4 g is as effective and well tolerated as 2 g twice-daily for inducing remission in patients with mild-to-moderately active ulcerative colitis (Clinicaltrials.gov: NCT00737789).